Look at Otezla ESTEEM 1 and ESTEEM 2 Phase 3 b study to really see what P is up against.
Celegene looked at efficacy in hard to treat psoriasis cases nails, scalp, palms of the hands, and soles of the feet in all classes of psoriasis patients. A second subset was palmoplantar psoriasis, (hands and soles of feet)
moderate to severe scalp psoriasis after 16 weeks of treatment was 41% score of 0 (no lesions)
moderate to severe palms and sole of feet showed 65% score of zero to 1 at 16 weeks. this compares to 30% in the placebo group. I find that placebo response rather high and hard to explain.
People are throwing numbers around here but to truly be compared to Otezla, P must eventually show equal or better efficacy in palmoplantar psoriasis, a very significant and difficult to treat group of psoriasis patients.
This will be the focus of any large phase 3 study in the future.
Market Data 
Markets 
AI
